GlaxoSmithKline announces 15% decline in 9MCY18 profits

Sep-18

Sep-17

% Change

Sales

                     25,274,071

                     23,882,711

5.83%

Cost of Sales

                  (18,908,179)

                  (17,281,119)

9.42%

Gross Profit

                       6,365,892

                       6,601,592

-3.57%

Selling, marketing and distribution expenses

                     (2,588,864)

                     (2,228,686)

16.16%

Administrative expenses

                        (776,093)

                        (727,941)

6.61%

Other operating expenses

                        (298,761)

                        (315,862)

-5.41%

Other income

                           590,607

                           362,838

62.77%

Profit from operations

                       3,292,781

                       3,691,941

-10.81%

Finance cost

                           (81,301)

                           (22,278)

264.94%

Profit before taxation

                       3,211,480

                       3,669,663

-12.49%

Taxation

                     (1,366,134)

                     (1,418,025)

-3.66%

Profit after taxation from continuing operations

                       1,845,346

                       2,251,638

-18.04%

(Loss)/Profit after taxation from discontinued operations

                             26,029

                           (35,695)

-172.92%

Total profit after taxation

                       1,871,375

                       2,215,943

-15.55%

Earnings per share (Rupees)

                                  5.87

                                  6.96

-15.66%